Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 41 entries
Sorted by: Best Match Show Resources per page
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Oncoimmunology

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.
PMID: 28405498
Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated...

Cite
Klein C, Waldhauer I, Nicolini VG, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306doi: 10.1080/2162402X.2016.1277306.
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., Lang, S., Roemmele, M., Hofer, T., van Puijenbroek, E., Wittig, D., Moser, S., Ast, O., Brünker, P., Gorr, I. H., Neumann, S., de Vera Mudry, M. C., Hinton, H., Crameri, F., Saro, J., Evers, S., Gerdes, C., Bacac, M., van Dongen, G., Moessner, E., & Umaña, P. (2017). Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology, 6(3), e1277306. https://doi.org/10.1080/2162402X.2016.1277306
Klein, Christian, et al. "Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines." Oncoimmunology vol. 6,3 (2017): e1277306. doi: https://doi.org/10.1080/2162402X.2016.1277306
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. PMID: 28405498; PMCID: PMC5384349.
Copy Download .nbib Format: NLM
Multicomponent synthesis of dihydropyrimidines and thiazines.

Chemistry (Weinheim an der Bergstrasse, Germany)

Vugts DJ, Koningstein MM, Schmitz RF, de Kanter FJ, Groen MB, Orru RV.
PMID: 16847990
Chemistry. 2006 Sep 18;12(27):7178-89. doi: 10.1002/chem.200600168.

A broad range of differently substituted dihydropyrimidines and thiazines can be efficiently prepared by using a four-component reaction between phosphonates, nitriles, aldehydes, and iso(thio)cyanates. The scope and limitations of this multicomponent reaction are fully described. Variation of all four...

Cite
Vugts DJ, Koningstein MM, Schmitz RF, et al. Multicomponent synthesis of dihydropyrimidines and thiazines. Chemistry. 2006;12(27):7178-89doi: 10.1002/chem.200600168.
Vugts, D. J., Koningstein, M. M., Schmitz, R. F., de Kanter, F. J., Groen, M. B., & Orru, R. V. (2006). Multicomponent synthesis of dihydropyrimidines and thiazines. Chemistry (Weinheim an der Bergstrasse, Germany), 12(27), 7178-89. https://doi.org/10.1002/chem.200600168
Vugts, Danielle J, et al. "Multicomponent synthesis of dihydropyrimidines and thiazines." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 12,27 (2006): 7178-89. doi: https://doi.org/10.1002/chem.200600168
Vugts DJ, Koningstein MM, Schmitz RF, de Kanter FJ, Groen MB, Orru RV. Multicomponent synthesis of dihydropyrimidines and thiazines. Chemistry. 2006 Sep 18;12(27):7178-89. doi: 10.1002/chem.200600168. PMID: 16847990.
Copy Download .nbib Format: NLM
ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape.

Molecular imaging and biology

Zeglis BM, Vugts DJ.
PMID: 28194633
Mol Imaging Biol. 2017 Jun;19(3):325-327. doi: 10.1007/s11307-017-1053-2.

The core mission of the Early Stage Professionals in Molecular Imaging Sciences (ESPMIS) Interest Group is to help young scientists navigate the professional landscape of molecular imaging. Since its formation in early 2015, ESPMIS has used the annual World...

Cite
Zeglis BM, Vugts DJ. ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape. Mol Imaging Biol. 2017;19(3):325-327doi: 10.1007/s11307-017-1053-2.
Zeglis, B. M., & Vugts, D. J. (2017). ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape. Molecular imaging and biology, 19(3), 325-327. https://doi.org/10.1007/s11307-017-1053-2
Zeglis, Brian M, and Vugts, Danielle J. "ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape." Molecular imaging and biology vol. 19,3 (2017): 325-327. doi: https://doi.org/10.1007/s11307-017-1053-2
Zeglis BM, Vugts DJ. ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape. Mol Imaging Biol. 2017 Jun;19(3):325-327. doi: 10.1007/s11307-017-1053-2. PMID: 28194633; PMCID: PMC6466623.
Copy Download .nbib Format: NLM
Towards PET imaging of the dynamic phenotypes of microglia.

Clinical and experimental immunology

Beaino W, Janssen B, Vugts DJ, de Vries HE, Windhorst AD.
PMID: 34331705
Clin Exp Immunol. 2021 Dec;206(3):282-300. doi: 10.1111/cei.13649. Epub 2021 Aug 16.

There is increasing evidence showing the heterogeneity of microglia activation in neuroinflammatory and neurodegenerative diseases. It has been hypothesized that pro-inflammatory microglia are detrimental and contribute to disease progression, while anti-inflammatory microglia play a role in damage repair and...

Cite
Beaino W, Janssen B, Vugts DJ, et al. Towards PET imaging of the dynamic phenotypes of microglia. Clin Exp Immunol. 2021;206(3):282-300doi: 10.1111/cei.13649.
Beaino, W., Janssen, B., Vugts, D. J., de Vries, H. E., & Windhorst, A. D. (2021). Towards PET imaging of the dynamic phenotypes of microglia. Clinical and experimental immunology, 206(3), 282-300. https://doi.org/10.1111/cei.13649
Beaino, Wissam, et al. "Towards PET imaging of the dynamic phenotypes of microglia." Clinical and experimental immunology vol. 206,3 (2021): 282-300. doi: https://doi.org/10.1111/cei.13649
Beaino W, Janssen B, Vugts DJ, de Vries HE, Windhorst AD. Towards PET imaging of the dynamic phenotypes of microglia. Clin Exp Immunol. 2021 Dec;206(3):282-300. doi: 10.1111/cei.13649. Epub 2021 Aug 16. PMID: 34331705; PMCID: PMC8561701.
Copy Download .nbib Format: NLM
First-in-human study of .

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Niemeijer AN, Oprea Lager DE, Huisman MC, Hoekstra OS, Boellaard R, van de Veen B, Bahce I, Vugts DJ, van Dongen GA, Thunnissen E, Smit E, de Langen AJ.
PMID: 34272316
J Nucl Med. 2021 Jul 16; doi: 10.2967/jnumed.121.261926. Epub 2021 Jul 16.

No abstract available.

Cite
Niemeijer AN, Oprea Lager DE, Huisman MC, et al. First-in-human study of . J Nucl Med. 2021;doi: 10.2967/jnumed.121.261926.
Niemeijer, A. N., Oprea Lager, D. E., Huisman, M. C., Hoekstra, O. S., Boellaard, R., van de Veen, B., Bahce, I., Vugts, D. J., van Dongen, G. A., Thunnissen, E., Smit, E., & de Langen, A. J. (2021). First-in-human study of . Journal of nuclear medicine : official publication, Society of Nuclear Medicine, . https://doi.org/10.2967/jnumed.121.261926
Niemeijer, Anna-Larissa Nadia, et al. "First-in-human study of ." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. (2021). doi: https://doi.org/10.2967/jnumed.121.261926
Niemeijer AN, Oprea Lager DE, Huisman MC, Hoekstra OS, Boellaard R, van de Veen B, Bahce I, Vugts DJ, van Dongen GA, Thunnissen E, Smit E, de Langen AJ. First-in-human study of . J Nucl Med. 2021 Jul 16; doi: 10.2967/jnumed.121.261926. Epub 2021 Jul 16. PMID: 34272316.
Copy Download .nbib Format: NLM
Utilization of electronic health records for the assessment of adiponectin receptor autoantibodies during the progression of cardio-metabolic comorbidities.

Archives of autoimmune diseases

Pugia MJ, Pradhan M, Qi R, Eastes DL, Vorsilak A, Mills BJ, Baird Z, Wijeratne A, McAhren SM, Mosley A, Shekhar A, Robertson DH.
PMID: 33511378
Arch Autoimmune Dis. 2020;1(1):17-27. doi: 10.46439/autoimmune.1.004.

BACKGROUND: Diabetes is a complex, multi-symptomatic disease whose complications drives increases in healthcare costs as the diabetes prevalence grows rapidly world-wide. Real-world electronic health records (EHRs) coupled with patient biospecimens, biological understanding, and technologies can characterize emerging diagnostic autoimmune...

Cite
Pugia MJ, Pradhan M, Qi R, et al. Utilization of electronic health records for the assessment of adiponectin receptor autoantibodies during the progression of cardio-metabolic comorbidities. Arch Autoimmune Dis. 2020;1(1):17-27doi: 10.46439/autoimmune.1.004.
Pugia, M. J., Pradhan, M., Qi, R., Eastes, D. L., Vorsilak, A., Mills, B. J., Baird, Z., Wijeratne, A., McAhren, S. M., Mosley, A., Shekhar, A., & Robertson, D. H. (2020). Utilization of electronic health records for the assessment of adiponectin receptor autoantibodies during the progression of cardio-metabolic comorbidities. Archives of autoimmune diseases, 1(1), 17-27. https://doi.org/10.46439/autoimmune.1.004
Pugia, Michael J, et al. "Utilization of electronic health records for the assessment of adiponectin receptor autoantibodies during the progression of cardio-metabolic comorbidities." Archives of autoimmune diseases vol. 1,1 (2020): 17-27. doi: https://doi.org/10.46439/autoimmune.1.004
Pugia MJ, Pradhan M, Qi R, Eastes DL, Vorsilak A, Mills BJ, Baird Z, Wijeratne A, McAhren SM, Mosley A, Shekhar A, Robertson DH. Utilization of electronic health records for the assessment of adiponectin receptor autoantibodies during the progression of cardio-metabolic comorbidities. Arch Autoimmune Dis. 2020;1(1):17-27. doi: 10.46439/autoimmune.1.004. PMID: 33511378; PMCID: PMC7839988.
Copy Download .nbib Format: NLM
Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes.

Archives of autoimmune diseases

Frabutt D, Stull N, Pineros AR, Tersey SA, Scheuner D, Mastracci TL, Pugia MJ.
PMID: 34414399
Arch Autoimmune Dis. 2020;1(1):3-13. doi: 10.46439/autoimmune.1.002.

The protein hormone adiponectin regulates glucose and fatty acid metabolism by binding to two PAQR-family receptors (AdipoR1 and AdipoR2). Both receptors feature a C-terminal segment which is released by proteolysis to form a freely circulating C-terminal fragment (CTF) found...

Cite
Frabutt D, Stull N, Pineros AR, et al. Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes. Arch Autoimmune Dis. 2020;1(1):3-13doi: 10.46439/autoimmune.1.002.
Frabutt, D., Stull, N., Pineros, A. R., Tersey, S. A., Scheuner, D., Mastracci, T. L., & Pugia, M. J. (2020). Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes. Archives of autoimmune diseases, 1(1), 3-13. https://doi.org/10.46439/autoimmune.1.002
Frabutt, Dylan, et al. "Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes." Archives of autoimmune diseases vol. 1,1 (2020): 3-13. doi: https://doi.org/10.46439/autoimmune.1.002
Frabutt D, Stull N, Pineros AR, Tersey SA, Scheuner D, Mastracci TL, Pugia MJ. Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes. Arch Autoimmune Dis. 2020;1(1):3-13. doi: 10.46439/autoimmune.1.002. PMID: 34414399; PMCID: PMC8372748.
Copy Download .nbib Format: NLM
Comparison of analytical methods for antibody conjugates with application in nuclear imaging - Report from the trenches.

Nuclear medicine and biology

Feiner IVJ, Longo B, Gómez-Vallejo V, Calvo J, Chomet M, Vugts DJ, Windhorst AD, Padro D, Zanda M, Rejc L, Llop J.
PMID: 34492606
Nucl Med Biol. 2021 Nov-Dec;102:24-33. doi: 10.1016/j.nucmedbio.2021.08.001. Epub 2021 Aug 18.

INTRODUCTION: Monoclonal antibodies (mAbs) are widely used in nuclear imaging. Radiolabelling with positron emitting radionuclides, typically radiometals, requires the incorporation of a bifunctional chelator for the formation of the radiometal-mAb complex. Additionally, mAbs can be conjugated with small molecules...

Cite
Feiner IVJ, Longo B, Gómez-Vallejo V, et al. Comparison of analytical methods for antibody conjugates with application in nuclear imaging - Report from the trenches. Nucl Med Biol. 2021;102:24-33doi: 10.1016/j.nucmedbio.2021.08.001.
Feiner, I. V. J., Longo, B., Gómez-Vallejo, V., Calvo, J., Chomet, M., Vugts, D. J., Windhorst, A. D., Padro, D., Zanda, M., Rejc, L., & Llop, J. (2021). Comparison of analytical methods for antibody conjugates with application in nuclear imaging - Report from the trenches. Nuclear medicine and biology, 10224-33. https://doi.org/10.1016/j.nucmedbio.2021.08.001
Feiner, Irene V J, et al. "Comparison of analytical methods for antibody conjugates with application in nuclear imaging - Report from the trenches." Nuclear medicine and biology vol. 102 (2021): 24-33. doi: https://doi.org/10.1016/j.nucmedbio.2021.08.001
Feiner IVJ, Longo B, Gómez-Vallejo V, Calvo J, Chomet M, Vugts DJ, Windhorst AD, Padro D, Zanda M, Rejc L, Llop J. Comparison of analytical methods for antibody conjugates with application in nuclear imaging - Report from the trenches. Nucl Med Biol. 2021 Nov-Dec;102:24-33. doi: 10.1016/j.nucmedbio.2021.08.001. Epub 2021 Aug 18. PMID: 34492606.
Copy Download .nbib Format: NLM
State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET.

Bioconjugate chemistry

Chomet M, van Dongen GAMS, Vugts DJ.
PMID: 33974403
Bioconjug Chem. 2021 Jul 21;32(7):1315-1330. doi: 10.1021/acs.bioconjchem.1c00136. Epub 2021 May 11.

Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is preferably fast, mild, efficient, and reproducible, especially when applied for human use in a current Good...

Cite
Chomet M, van Dongen GAMS, Vugts DJ. State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjug Chem. 2021;32(7):1315-1330doi: 10.1021/acs.bioconjchem.1c00136.
Chomet, M., van Dongen, G. A. M. S., & Vugts, D. J. (2021). State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjugate chemistry, 32(7), 1315-1330. https://doi.org/10.1021/acs.bioconjchem.1c00136
Chomet, Marion, et al. "State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET." Bioconjugate chemistry vol. 32,7 (2021): 1315-1330. doi: https://doi.org/10.1021/acs.bioconjchem.1c00136
Chomet M, van Dongen GAMS, Vugts DJ. State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjug Chem. 2021 Jul 21;32(7):1315-1330. doi: 10.1021/acs.bioconjchem.1c00136. Epub 2021 May 11. PMID: 33974403; PMCID: PMC8299458.
Copy Download .nbib Format: NLM
Fluorine-18 labelled Ruppert-Prakash reagent ([.

Chemical communications (Cambridge, England)

Pees A, Vosjan MJWD, Vasdev N, Windhorst AD, Vugts DJ.
PMID: 33942818
Chem Commun (Camb). 2021 May 27;57(43):5286-5289. doi: 10.1039/d1cc01789f.

This article describes the first synthesis and application of fluorine-18 labelled Ruppert-Prakash reagent [18F]Me3SiCF3. [18F]Me3SiCF3 was synthesized from [18F]fluoroform with radiochemical yields of 85-95% and radiochemical purities of >95% within 20 minutes. 18F-trifluoromethylated compounds were successfully prepared by reaction...

Cite
Pees A, Vosjan MJWD, Vasdev N, et al. Fluorine-18 labelled Ruppert-Prakash reagent ([. Chem Commun (Camb). 2021;57(43):5286-5289doi: 10.1039/d1cc01789f.
Pees, A., Vosjan, M. J. W. D., Vasdev, N., Windhorst, A. D., & Vugts, D. J. (2021). Fluorine-18 labelled Ruppert-Prakash reagent ([. Chemical communications (Cambridge, England), 57(43), 5286-5289. https://doi.org/10.1039/d1cc01789f
Pees, Anna, et al. "Fluorine-18 labelled Ruppert-Prakash reagent ([." Chemical communications (Cambridge, England) vol. 57,43 (2021): 5286-5289. doi: https://doi.org/10.1039/d1cc01789f
Pees A, Vosjan MJWD, Vasdev N, Windhorst AD, Vugts DJ. Fluorine-18 labelled Ruppert-Prakash reagent ([. Chem Commun (Camb). 2021 May 27;57(43):5286-5289. doi: 10.1039/d1cc01789f. PMID: 33942818.
Copy Download .nbib Format: NLM
[Rest in the treatment of pulmonary tuberculosis].

La Clinica terapeutica

Vuga D.
PMID: 5328745
Clin Ter. 1966 Feb 28;36(4):356-60.

No abstract available.

Cite
Vuga D. Il riposo nella cura della tubercolosi polmonare. [Rest in the treatment of pulmonary tuberculosis]. Clin Ter. 1966;36(4):356-60
Vuga, D. (1966). Il riposo nella cura della tubercolosi polmonare. [Rest in the treatment of pulmonary tuberculosis]. La Clinica terapeutica, 36(4), 356-60.
Vuga, D. "Il riposo nella cura della tubercolosi polmonare." [Rest in the treatment of pulmonary tuberculosis]. La Clinica terapeutica vol. 36,4 (1966): 356-60.
Vuga D. Il riposo nella cura della tubercolosi polmonare. [Rest in the treatment of pulmonary tuberculosis]. Clin Ter. 1966 Feb 28;36(4):356-60. Italian. PMID: 5328745.
Copy Download .nbib Format: NLM
The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans.

EJNMMI research

Thorneloe KS, Sepp A, Zhang S, Galinanes-Garcia L, Galette P, Al-Azzam W, Vugts DJ, van Dongen G, Elsinga P, Wiegers J, Glaudemans AWJM, Vincent V, Renaux J, Szapacs M, Birchler M, Cleveland M, Bergstrom M, Davies M.
PMID: 31115711
EJNMMI Res. 2019 May 21;9(1):45. doi: 10.1186/s13550-019-0514-9.

CONCLUSION: Evaluating the biodistribution of

Cite
Thorneloe KS, Sepp A, Zhang S, et al. The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Res. 2019;9(1):45doi: 10.1186/s13550-019-0514-9.
Thorneloe, K. S., Sepp, A., Zhang, S., Galinanes-Garcia, L., Galette, P., Al-Azzam, W., Vugts, D. J., van Dongen, G., Elsinga, P., Wiegers, J., Glaudemans, A. W. J. M., Vincent, V., Renaux, J., Szapacs, M., Birchler, M., Cleveland, M., Bergstrom, M., & Davies, M. (2019). The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI research, 9(1), 45. https://doi.org/10.1186/s13550-019-0514-9
Thorneloe, Kevin S, et al. "The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans." EJNMMI research vol. 9,1 (2019): 45. doi: https://doi.org/10.1186/s13550-019-0514-9
Thorneloe KS, Sepp A, Zhang S, Galinanes-Garcia L, Galette P, Al-Azzam W, Vugts DJ, van Dongen G, Elsinga P, Wiegers J, Glaudemans AWJM, Vincent V, Renaux J, Szapacs M, Birchler M, Cleveland M, Bergstrom M, Davies M. The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Res. 2019 May 21;9(1):45. doi: 10.1186/s13550-019-0514-9. PMID: 31115711; PMCID: PMC6529487.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 41 entries